engleski

Development of an organic arsenic derivative as a therapy for leukaemia

Use of arsenic trioxide (ATO) in other malignancies than APL is limited by its' toxicity. In contrast, organic arsenic derivatives (OAD) are much less toxic ; hepatic methylation of inorganic arsenic to yield OAD is mechanism of detoxification. We have confirmed potent activity of SGLU1 (new OAD) against human leukemia, lymphoma, multiple myeloma cell lines and leukemic cells from leukemia patients, with activity comparable to that of ATO. Mechanism of action of <SGLU1 and ATO differs significantly. SGLU1 is significantly less toxic to healthy donor cells than ATO. This work has high potential for identification of a new therapeutic approach for patients with leukemia.

arsenic trioxide; organic arsenic derivatives; toxicity

nije evidentirano